Literature DB >> 15677797

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study.

Ann Marie McNeill1, Wayne D Rosamond, Cynthia J Girman, Sherita Hill Golden, Maria I Schmidt, Honey E East, Christie M Ballantyne, Gerardo Heiss.   

Abstract

OBJECTIVE: To assess the magnitude of the association between the National Cholesterol Education Program's Third Adult Treatment Panel Report (ATP III) definition of the metabolic syndrome and cardiovascular disease (CVD). RESEARCH DESIGN AND METHODS: Cox regression was used to estimate the relative risk of incident coronary heart disease (CHD) and stroke among 12,089 black and white middle-aged individuals in the Atherosclerosis Risk in Communities (ARIC) study.
RESULTS: The metabolic syndrome was present in approximately 23% of individuals without diabetes or prevalent CVD at baseline. Over an average of 11 years of follow-up, 879 incident CHD and 216 ischemic stroke events occurred. Among the components of the metabolic syndrome, elevated blood pressure and low levels of HDL cholesterol exhibited the strongest associations with CHD. Men and women with the metabolic syndrome were approximately 1.5 and 2 times more likely to develop CHD than control subjects after adjustment for age, smoking, LDL cholesterol, and race/ARIC center (sex interaction P < 0.03). Similar associations were found between the metabolic syndrome and incident ischemic stroke. Comparison of receiver operating characteristic curves indicated that the metabolic syndrome did not materially improve CHD risk prediction beyond the level achieved by the Framingham Risk Score (FRS).
CONCLUSIONS: Individuals without diabetes or CVD, but with the metabolic syndrome, were at increased risk for long-term cardiovascular outcomes, although statistical models suggested that most of that risk was accounted for by the FRS. Nevertheless, identification of individuals with the metabolic syndrome may provide opportunities to intervene earlier in the development of shared disease pathways that predispose individuals to both CVD and diabetes.

Entities:  

Mesh:

Year:  2005        PMID: 15677797     DOI: 10.2337/diacare.28.2.385

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  250 in total

1.  Effects of etanercept in patients with the metabolic syndrome.

Authors:  L Elizabeth Bernstein; Jacqueline Berry; Sunnie Kim; Bridget Canavan; Steven K Grinspoon
Journal:  Arch Intern Med       Date:  2006-04-24

2.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

3.  Insulin resistance is not necessarily an essential element of metabolic syndrome.

Authors:  Rudruidee Karnchanasorn; Horng-Yi Ou; Lee-Ming Chuang; Ken C Chiu
Journal:  Endocrine       Date:  2012-05-29       Impact factor: 3.633

4.  Prevalence of metabolic syndrome with International Diabetes Federation Criteria and ATP III Program in patients 65 years of age or older.

Authors:  D A De Luis; R Lopez Mongil; M Gonzalez Sagrado; J A Lopez Trigo; P F Mora; J Castrodeza Sanz
Journal:  J Nutr Health Aging       Date:  2010-05       Impact factor: 4.075

5.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

6.  Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial.

Authors:  Fernanda M Consolim-Colombo; Carine T Sangaleti; Fernando O Costa; Tercio L Morais; Heno F Lopes; Josiane M Motta; Maria C Irigoyen; Luiz A Bortoloto; Carlos Eduardo Rochitte; Yael Tobi Harris; Sanjaya K Satapathy; Peder S Olofsson; Meredith Akerman; Sangeeta S Chavan; Meggan MacKay; Douglas P Barnaby; Martin L Lesser; Jesse Roth; Kevin J Tracey; Valentin A Pavlov
Journal:  JCI Insight       Date:  2017-07-20

7.  Anti-inflammatory effect of amlodipine plus atorvastatin treatment on carotid atherosclerosis in zucker metabolic syndrome rats.

Authors:  Xuemei Zhang; Fengfeng Tian; Hiromi Kawai; Tomoko Kurata; Shoko Deguchi; Kentaro Deguchi; Jingwei Shang; Ning Liu; Wentao Liu; Yoshio Ikeda; Tohru Matsuura; Tatsushi Kamiya; Koji Abe
Journal:  Transl Stroke Res       Date:  2012-07-21       Impact factor: 6.829

8.  Severity of the metabolic syndrome as a predictor of type 2 diabetes between childhood and adulthood: the Princeton Lipid Research Cohort Study.

Authors:  Mark D DeBoer; Matthew J Gurka; Jessica G Woo; John A Morrison
Journal:  Diabetologia       Date:  2015-09-17       Impact factor: 10.122

9.  Plasma lipid concentrations in nondiabetic African American adults: associations with insulin resistance and the metabolic syndrome.

Authors:  Elizabeth Stein; Harvey Kushner; Samuel Gidding; Bonita Falkner
Journal:  Metabolism       Date:  2007-07       Impact factor: 8.694

Review 10.  Metabolic syndrome: demographic features, etiology, and clinical management.

Authors:  Kathleen L Wyne
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.